You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

AstraZeneca says DOJ closes probe into drug trial

WASHINGTON — British drugmaker AstraZeneca says the Department of Justice has closed its investigation into a clinical trial of the company’s blood thinner Brilinta, and plans no further action.

The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.

Continue reading below

The study, dubbed PLATO, showed that patients taking Brilinta instead of competing drug Plavix were less likely to experience various heart-related problems, including heart attack, stroke and death.

News of the investigation has raised questions about the validity of the trial and the benefits of the drug, which hit the market in 2011.

The London-based drugmaker said in a statement Tuesday: ‘‘AstraZeneca has always had absolute confidence in the integrity of the PLATO trial.’’

Brilinta had sales of $283 million last year.

 Correction: Because of an editing error, the headline on the print version of this story incorrectly characterized the status of the US inquiry into Brilinta.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.